​

Lyell Immunopharma (LYEL) Revenue & Revenue Breakdown

OverviewOwnershipFinancialsChart

Lyell Immunopharma Revenue Highlights

0

Latest Revenue (Q)

$11.00K

Main Segment (Y)

Reportable segment

Lyell Immunopharma Revenue by Period

Lyell Immunopharma Revenue by Year

DateRevenueChange
2024-12-31--100.00%
2023-12-31$130.00K-99.85%
2022-12-31$84.68M695.15%
2021-12-31$10.65M37.31%
2020-12-31$7.76M1080.52%
2019-12-31$657.00K-

Lyell Immunopharma generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Lyell Immunopharma Revenue by Quarter

DateRevenueChange
2024-12-31$11.00K-67.65%
2024-09-30$34.00K161.54%
2024-06-30$13.00K333.33%
2024-03-31$3.00K-76.92%
2023-12-31$13.00K-48.00%
2023-09-30$25.00K-7.41%
2023-06-30$27.00K-58.46%
2023-03-31$65.00K34.34%
2022-12-31$48.39K1512.87%
2022-09-30$3.00K-99.99%
2022-06-30$35.74M6363.11%
2022-03-31$553.00K-80.40%
2021-12-31$2.82M2.43%
2021-09-30$2.75M4.83%
2021-06-30$2.63M7.48%
2021-03-31$2.44M5.75%
2020-12-31$2.31M116.07%
2020-09-30$1.07M-65.68%
2020-06-30$3.12M148.25%
2020-03-31$1.26M-

Lyell Immunopharma generated $11.00K in revenue during Q4 2024, up -67.65% compared to the previous quarter, and up 44.00% compared to the same period a year ago.

Lyell Immunopharma Revenue Breakdown

Lyell Immunopharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
Reportable segment$61.00K

Lyell Immunopharma's latest annual revenue breakdown by segment (product or service), as of Dec 24: Reportable segment (100.00%).

Quarterly Revenue by Product

Product/ServiceMar 25
Reportable segment$7.00K

Lyell Immunopharma's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Reportable segment (100.00%).

Lyell Immunopharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
GLUEMonte Rosa Therapeutics$75.62M$60.65M
MRUSMerus$36.13M$9.14M
CCCCC4 Therapeutics$20.76M$5.18M
GBIOGeneration Bio$19.89M$4.19M
KRONKronos Bio$9.85M$2.27M
NUVBNuvation Bio$7.87M$5.71M
IPSCCentury Therapeutics$6.59M$109.16M
STTKShattuck Labs$5.72M-
CRNXCrinetics Pharmaceuticals$1.04M-
INBXInhibrx Biosciences$200.00K$100.00K
CGEMCullinan Oncology--
RVMDRevolution Medicines--
EWTXEdgewise Therapeutics--
SANASana Bio--
NKTXNkarta--
MLYSMineralys Therapeutics--
LYELLyell Immunopharma-$11.00K

LYEL Revenue FAQ

What is Lyell Immunopharma’s yearly revenue?

Lyell Immunopharma's yearly revenue for 2024 was $0, representing a decrease of -100.00% compared to 2023. The company's yearly revenue for 2023 was $130K, representing a decrease of -99.85% compared to 2022. LYEL's yearly revenue for 2022 was $84.68M, representing an increase of 695.15% compared to 2021.

What is Lyell Immunopharma’s quarterly revenue?

Lyell Immunopharma's quarterly revenue for Q4 2024 was $11K, a -67.65% decrease from the previous quarter (Q3 2024), and a -15.38% decrease year-over-year (Q4 2023). The company's quarterly revenue for Q3 2024 was $34K, a 161.54% increase from the previous quarter (Q2 2024), and a 36.00% increase year-over-year (Q3 2023). LYEL's quarterly revenue for Q2 2024 was $13K, a 333.33% increase from the previous quarter (Q1 2024), and a -51.85% decrease year-over-year (Q2 2023).

What is Lyell Immunopharma’s revenue growth rate?

Lyell Immunopharma's revenue growth rate for the last 3 years (2022-2024) was -100.00%, and for the last 5 years (2020-2024) was -100.00%.

What are Lyell Immunopharma’s revenue streams?

Lyell Immunopharma's revenue streams in c 24 are Reportable segment

What is Lyell Immunopharma’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Lyell Immunopharma was Reportable segment. This segment made a revenue of $61K, representing 100.00% of the company's total revenue.